News | March 28, 2022
Tata Capital Healthcare Fund II raises Rs 955 crore
The fund will take equity positions in India-focused healthcare and life sciences-related companies
The fund will take equity positions in India-focused healthcare and life sciences-related companies
Seasoned governance expert and board leader brings extensive experience in strategic oversight, risk management, and corporate governance across multiple sectors
Biocon will acquire the residual stake held by Mylan (Viatris) for a total consideration of US$ 815 million
Witnessing sizable consolidation (M& A) activity with Domestic Formulations and Hospitals being two areas wherein maximum M&A has occurred.
Biocon Ltd, an innovation-led global biopharmaceuticals company, has announced that the Board of its subsidiary Biocon Biologics Ltd has approved a primary equity investment of US $75 million (Rs. 555 crores) by Abu Dhabi based ADQ, one of the region’s largest holding companies.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
